Sign In
Buy CRNX
$33.09
+0.480 (+1.47%)
At Close: Jun 03, 2026
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy' Initiative to Empower People Across Endocrine Disease Communities
04:05pm, Tuesday, 02'nd Jun 2026
Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
04:55am, Tuesday, 02'nd Jun 2026
Oral presentation features open label extension PALSONIFY (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U. S. and E. U. approvals Two oral presentations of
Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
04:55am, Tuesday, 02'nd Jun 2026
Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
04:05pm, Friday, 22'nd May 2026
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taki
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?
01:50pm, Monday, 18'th May 2026
Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.
Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript
02:11am, Friday, 08'th May 2026
Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates
06:55pm, Thursday, 07'th May 2026
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to a loss of $1.04 per share a year ago.
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
04:05pm, Thursday, 07'th May 2026
PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter Management Hosting Conference Call at 4:30 p.m. ET To
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for
11:06am, Thursday, 30'th Apr 2026
CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medica
Jeff Knight Sells 85,163 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock
04:19am, Sunday, 12'th Apr 2026
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX - Get Free Report) insider Jeff Knight sold 85,163 shares of the company's stock in a transaction that occurred on Wednesday, April 8th. The stock was sol
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
04:05pm, Wednesday, 08'th Apr 2026
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Analysts
04:43am, Sunday, 29'th Mar 2026
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the stock, MarketBeat repo
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More
07:56pm, Friday, 27'th Mar 2026
A director of Crinetics Pharmaceuticals reported that he sold 5,000 shares of the company for a transaction value of approximately $180,761 on March 12, 2026. The sale represented 23.47% of Coelho's d
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil's National Health S
